

As part of the lecture series organized by the MIPLC and the MPI,

Ms. Sarah Columbia

will speak on

“The Most Important Intellectual Property Developments in the US and How They Impact Your Business”

Place: Marstallstr. 8, 2nd Floor, Room 220

Date: Monday, June 12, 2017 – 6:30 – 8:00pm

Abstract

This lecture will cover recent developments in US administrative and judicial precedent and how those developments are impacting the US intellectual property system, with a particular focus on how recent developments may impact companies headquartered outside the United States.

The lecture will include a presentation of the most important recent decisions by the US Supreme Court and the Federal Circuit Court of Appeals, including *Samsung v Apple*, *Enfish v Microsoft*, *Cuozzo*, *SCA Hygeine*, *Halo*, *Amgen v Sandoz*, *T.C. Heartland* and others, with a focus on the impact those decisions are having on US intellectual property litigation and on the strategies being employed for the protection of intellectual property in the United States. In particular, we will discuss the increased pressure on patentable subject matter in both the high tech and life sciences fields, the impact of Highmark and Octane Fitness on the award of attorneys' fees and how that is influencing behavior, the changing strategies in light of the downward pressure on damages awards in light of VirnetX, Apple v Samsung, and other cases. Depending upon whether the US Supreme Court has issued its decision in the TC Heartland case, we will discuss the decision (or potential decision) and its impact – both legal and practical – on US patent litigation.

Sarah Chapin Columbia is a partner in the law firm of McDermott Will & Emery LLP and is global head of the Intellectual Property Practice Group. Her practice focuses on intellectual prop-

DM_US 81397791-1.T10373.0010



erty litigation including patent, trademark, copyright and trade secret matters. She also counsels clients on overall intellectual property strategy and positioning, including litigation avoidance, and in representing clients in private arbitrations both in the United States and in Europe.

Sarah has appeared in several state, federal district and appellate courts. She represents clients across several industries including semiconductor, pharmaceutical, biotechnology, Internet, hardware and software, medical device and manufacturing companies. Sarah's recent significant cases include high-profile jury trial wins for Amgen in a case involving monoclonal antibodies and another jury trial win for smartphone maker BlackBerry.

Professor Dr. Josef Drexl, LL.M. (Berkeley)
Director, Max Planck Institute for Innovation & Competition
Managing Director, MIPLC